Asia Pacific Leukemia Therapeutics Market Size, Share & Industry Trends Analysis Report By Drug Class (Targeted Therapy & Immunotherapy and Chemotherapy), By Distribution Channel, By Type, By Country and Growth Forecast, 2023

List of Tables

The Asia Pacific Leukemia Therapeutics Market would witness market growth of 6.6% CAGR during the forecast period (2023-2029).

Rising rates of cancer, particularly blood cancer, are fueling a demand for more efficient therapies, which is propelling the market's expansion. The market is expanding further because of rising spending on the creation of novel treatments and improving healthcare infrastructure. Furthermore, the increased survival rate and minimal side effects of cutting-edge treatments like stem cell therapy and bone marrow transplant have created new opportunities for market expansion. Also, the population's changing dietary preferences, exposure to chemical mutation, and way of life are all driving the market's expansion.

Drug innovators would have lucrative market opportunities due to breakthrough therapy designations and fast approvals given by regulatory agencies. Middle-aged and elderly people are the main demographics affected by the condition. The scope for treatments is expanding due to recent discoveries in this field by research teams around the region. The market is also being driven by the action of newer acceptable growth and the introduction of new medications into existence.

Increased research & development of new cancer therapies as well as older people who require special care are both impacted by market growth. Increased government funding, a large patient population, and increased R&D activity all contribute to faster market growth in some regions. The introduction of medicines that are competently organized, effective, and have fewer side effects, as well as metabolic inhibitors and pipeline pharmaceuticals awaiting approval, are anticipated to support the expansion of the market.

The regional market participants could expand their products and obtain the largest revenue share with the aid of the expanding healthcare infrastructure and enhanced government initiatives. Furthermore, as people's disposable incomes expand in emerging nations, the region's healthcare infrastructure is advancing, which increases the accessibility of cutting-edge treatment options. Additionally, there is a large patient pool in nations like Korea and India. Therefore, it is anticipated that these factors will present growth opportunities for the market players active in the regional market during the forecast period.

The China market dominated the Asia Pacific Leukemia Therapeutics Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $849.7 million by 2029. The Japan market is estimated to grow a CAGR of 5.9% during (2023 - 2029). Additionally, The India market would display a CAGR of 7.3% during (2023 - 2029).

Based on Drug Class, the market is segmented into Targeted Therapy & Immunotherapy and Chemotherapy. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Providers. Based on Type, the market is segmented into Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia, Acute Myeloid Leukemia and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Gilead Sciences, Inc., Bristol Myers Squibb Company, Sanofi S.A., AbbVie, Inc., Teva Pharmaceuticals Industries Ltd., Lupin Limited, Amgen, Inc., Takeda Pharmaceutical Company Limited, Pfizer, Inc. and Novartis AG.

Scope of the Study

Market Segments covered in the Report:

By Drug Class

Targeted Therapy & Immunotherapy
Chemotherapy

By Distribution Channel

Hospital Pharmacies
Drug Store & Retail Pharmacies
Online Providers

By Type

Chronic Lymphocytic Leukemia
Acute Lymphocytic Leukemia
Chronic Myeloid Leukemia
Acute Myeloid Leukemia
Others

By Country

China
Japan
India
South Korea
Singapore
Malaysia
Rest of Asia Pacific

Companies Profiled

Gilead Sciences, Inc.
Bristol Myers Squibb Company
Sanofi S.A.
AbbVie, Inc.
Teva Pharmaceuticals Industries Ltd.
Lupin Limited
Amgen, Inc.
Takeda Pharmaceutical Company Limited
Pfizer, Inc.
Novartis AG

Unique Offerings from KBV Research

Exhaustive coverage
Highest number of market tables and figures
Subscription based model available
Guaranteed best price
Assured post sales research support with 10% customization free

Chapter 1. Market Scope & Methodology

1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
- 1.4.1 Asia Pacific Leukemia Therapeutics Market, by Drug Class
- 1.4.2 Asia Pacific Leukemia Therapeutics Market, by Distribution Channel
- 1.4.3 Asia Pacific Leukemia Therapeutics Market, by Type
- 1.4.4 Asia Pacific Leukemia Therapeutics Market, by Country
1.5 Methodology for the research

Chapter 2. Market Overview

2.1 Introduction
- 2.1.1 Overview
  - 2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
- 2.2.1 Market Drivers
- 2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global

3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
- 3.2.1 Partnerships, Collaborations and Agreements
- 3.2.2 Product Launches and Product Expansions
- 3.2.3 Acquisition and Mergers
- 3.2.4 Approvals & Trails
3.3 Top Winning Strategies
- 3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
- 3.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements: 2019, May - 2022, Dec) Leading Players

Chapter 4. Asia Pacific Leukemia Therapeutics Market by Drug Class

4.1 Asia Pacific Targeted Therapy & Immunotherapy Market by Country
4.2 Asia Pacific Chemotherapy Market by Country

Chapter 5. Asia Pacific Leukemia Therapeutics Market by Distribution Channel

5.1 Asia Pacific Hospital Pharmacies Market by Country
5.2 Asia Pacific Drug Store & Retail Pharmacies Market by Country
5.3 Asia Pacific Online Providers Market by Country

Chapter 6. Asia Pacific Leukemia Therapeutics Market by Type

6.1 Asia Pacific Chronic Lymphocytic Leukemia Market by Country
6.2 Asia Pacific Acute Lymphocytic Leukemia Market by Country
6.3 Asia Pacific Chronic Myeloid Leukemia Market by Country
6.4 Asia Pacific Acute Myeloid Leukemia Market by Country
6.5 Asia Pacific Others Market by Country

Chapter 7. Asia Pacific Leukemia Therapeutics Market by Country

7.1 China Leukemia Therapeutics Market
- 7.1.1 China Leukemia Therapeutics Market by Drug Class
- 7.1.2 China Leukemia Therapeutics Market by Distribution Channel
- 7.1.3 China Leukemia Therapeutics Market by Type
7.2 Japan Leukemia Therapeutics Market
- 7.2.1 Japan Leukemia Therapeutics Market by Drug Class
- 7.2.2 Japan Leukemia Therapeutics Market by Distribution Channel
- 7.2.3 Japan Leukemia Therapeutics Market by Type
7.3 India Leukemia Therapeutics Market
- 7.3.1 India Leukemia Therapeutics Market by Drug Class
- 7.3.2 India Leukemia Therapeutics Market by Distribution Channel
- 7.3.3 India Leukemia Therapeutics Market by Type
7.4 South Korea Leukemia Therapeutics Market
- 7.4.1 South Korea Leukemia Therapeutics Market by Drug Class
- 7.4.2 South Korea Leukemia Therapeutics Market by Distribution Channel
- 7.4.3 South Korea Leukemia Therapeutics Market by Type
7.5 Singapore Leukemia Therapeutics Market
- 7.5.1 Singapore Leukemia Therapeutics Market by Drug Class
- 7.5.2 Singapore Leukemia Therapeutics Market by Distribution Channel
- 7.5.3 Singapore Leukemia Therapeutics Market by Type
7.6 Malaysia Leukemia Therapeutics Market
- 7.6.1 Malaysia Leukemia Therapeutics Market by Drug Class
- 7.6.2 Malaysia Leukemia Therapeutics Market by Distribution Channel
- 7.6.3 Malaysia Leukemia Therapeutics Market by Type
7.7 Rest of Asia Pacific Leukemia Therapeutics Market
- 7.7.1 Rest of Asia Pacific Leukemia Therapeutics Market by Drug Class
- 7.7.2 Rest of Asia Pacific Leukemia Therapeutics Market by Distribution Channel
- 7.7.3 Rest of Asia Pacific Leukemia Therapeutics Market by Type

Chapter 8. Company Profiles

8.1 Gilead Sciences, Inc.
- 8.1.1 Company overview
- 8.1.2 Financial Analysis
- 8.1.3 Research & Development Expenses
- 8.1.4 Recent strategies and developments:
  - 8.1.4.1 Partnerships, Collaborations, and Agreements:
  - 8.1.4.2 Acquisition and Mergers:
8.2 Bristol Myers Squibb Company
- 8.2.1 Company Overview
- 8.2.2 Financial Analysis
- 8.2.3 Regional Analysis
- 8.2.4 Research & Development Expenses
- 8.2.5 Recent strategies and developments:
  - 8.2.5.1 Acquisition and Mergers:
  - 8.2.5.2 Partnerships, Collaborations and Agreements:
  - 8.2.5.3 Approvals and Trials:
8.3 Sanofi S.A.
- 8.3.1 Company Overview
- 8.3.2 Financial Analysis
- 8.3.3 Segmental and Regional Analysis
- 8.3.4 Research & Development Expense
- 8.3.5 Recent strategies and developments:
  - 8.3.5.1 Partnerships, Collaborations, and Agreements:
  - 8.3.5.2 Trials and Approvals:
  - 8.3.5.3 Acquisitions and Mergers:
8.4 AbbVie, Inc.
- 8.4.1 Company Overview
- 8.4.2 Financial Analysis
- 8.4.3 Regional Analysis
- 8.4.4 Research & Development Expense
- 8.4.5 Recent strategies and developments:
  - 8.4.5.1 Acquisition and Mergers:
  - 8.4.5.2 Approvals & Trials:
8.5 Teva Pharmaceutical Industries Ltd.
- 8.5.1 Company Overview
- 8.5.2 Financial Analysis
- 8.5.3 Regional Analysis
- 8.5.4 Research & Development Expenses
- 8.5.5 Recent strategies and developments:
  - 8.5.5.1 Product Launches and Product Expansions:
8.6 Lupin Limited
- 8.6.1 Company Overview
- 8.6.2 Financial Analysis
- 8.6.3 Recent strategies and developments:
  - 8.6.3.1 Product Launches and Product Expansions:
8.7 Amgen, Inc.
- 8.7.1 Company Overview
- 8.7.2 Financial Analysis
- 8.7.3 Regional Analysis
- 8.7.4 Research & Development Expenses
- 8.7.5 Recent strategies and developments:
  - 8.7.5.1 Trials and Approvals:
8.8 Takeda Pharmaceutical Company Limited
- 8.8.1 Company Overview
- 8.8.2 Financial Analysis
- 8.8.3 Regional Analysis
- 8.8.4 Research & Development Expense
- 8.8.5 Recent strategies and developments:
  - 8.8.5.1 Approvals & Trials:
8.9 Pfizer, Inc.
- 8.9.1 Company Overview
- 8.9.2 Financial Analysis
- 8.9.3 Regional & Segmental Analysis
- 8.9.4 Research & Development Expense
- 8.9.5 Recent strategies and developments:
  - 8.9.5.1 Approvals & Trials:
  - 8.9.5.2 Acquisition and Mergers:
8.10. Novartis AG
- 8.10.1 Company Overview
- 8.10.2 Financial Analysis
- 8.10.3 Research & Development Expense
- 8.10.4 Recent strategies and developments:
  - 8.10.4.1 Partnerships, Collaborations, and Agreements:
  - 8.10.4.2 Approvals & Trials:

LIST OF TABLES

TABLE 1 Asia Pacific Leukemia Therapeutics Market, 2019 - 2022, USD Million
TABLE 2 Asia Pacific Leukemia Therapeutics Market, 2023 - 2029, USD Million
TABLE 3 Partnerships, Collaborations and Agreements- Leukemia Therapeutics Market
TABLE 4 Product Launches And Product Expansions- Leukemia Therapeutics Market
TABLE 5 Acquisition and Mergers- Leukemia Therapeutics Market
TABLE 6 Approvals & Trials- Leukemia Therapeutics Market
TABLE 7 Asia Pacific Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
TABLE 8 Asia Pacific Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
TABLE 9 Asia Pacific Targeted Therapy & Immunotherapy Market by Country, 2019 - 2022, USD Million
TABLE 10 Asia Pacific Targeted Therapy & Immunotherapy Market by Country, 2023 - 2029, USD Million
TABLE 11 Asia Pacific Chemotherapy Market by Country, 2019 - 2022, USD Million
TABLE 12 Asia Pacific Chemotherapy Market by Country, 2023 - 2029, USD Million
TABLE 13 Asia Pacific Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 14 Asia Pacific Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 15 Asia Pacific Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 16 Asia Pacific Hospital Pharmacies Market by Country, 2023 - 2029, USD Million
TABLE 17 Asia Pacific Drug Store & Retail Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 18 Asia Pacific Drug Store & Retail Pharmacies Market by Country, 2023 - 2029, USD Million
TABLE 19 Asia Pacific Online Providers Market by Country, 2019 - 2022, USD Million
TABLE 20 Asia Pacific Online Providers Market by Country, 2023 - 2029, USD Million
TABLE 21 Asia Pacific Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
TABLE 22 Asia Pacific Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
TABLE 23 Asia Pacific Chronic Lymphocytic Leukemia Market by Country, 2019 - 2022, USD Million
TABLE 24 Asia Pacific Chronic Lymphocytic Leukemia Market by Country, 2023 - 2029, USD Million
TABLE 25 Asia Pacific Acute Lymphocytic Leukemia Market by Country, 2019 - 2022, USD Million
TABLE 26 Asia Pacific Acute Lymphocytic Leukemia Market by Country, 2023 - 2029, USD Million
TABLE 27 Asia Pacific Chronic Myeloid Leukemia Market by Country, 2019 - 2022, USD Million
TABLE 28 Asia Pacific Chronic Myeloid Leukemia Market by Country, 2023 - 2029, USD Million
TABLE 29 Asia Pacific Acute Myeloid Leukemia Market by Country, 2019 - 2022, USD Million
TABLE 30 Asia Pacific Acute Myeloid Leukemia Market by Country, 2023 - 2029, USD Million
TABLE 31 Asia Pacific Others Market by Country, 2019 - 2022, USD Million
TABLE 32 Asia Pacific Others Market by Country, 2023 - 2029, USD Million
TABLE 33 Asia Pacific Leukemia Therapeutics Market by Country, 2019 - 2022, USD Million
TABLE 34 Asia Pacific Leukemia Therapeutics Market by Country, 2023 - 2029, USD Million
TABLE 35 China Leukemia Therapeutics Market, 2019 - 2022, USD Million
TABLE 36 China Leukemia Therapeutics Market, 2023 - 2029, USD Million
TABLE 37 China Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
TABLE 38 China Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
TABLE 39 China Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 40 China Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 41 China Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
TABLE 42 China Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
TABLE 43 Japan Leukemia Therapeutics Market, 2019 - 2022, USD Million
TABLE 44 Japan Leukemia Therapeutics Market, 2023 - 2029, USD Million
TABLE 45 Japan Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
TABLE 46 Japan Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
TABLE 47 Japan Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 48 Japan Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 49 Japan Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
TABLE 50 Japan Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
TABLE 51 India Leukemia Therapeutics Market, 2019 - 2022, USD Million
TABLE 52 India Leukemia Therapeutics Market, 2023 - 2029, USD Million
TABLE 53 India Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
TABLE 54 India Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
TABLE 55 India Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 56 India Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 57 India Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
TABLE 58 India Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
TABLE 59 South Korea Leukemia Therapeutics Market, 2019 - 2022, USD Million
TABLE 60 South Korea Leukemia Therapeutics Market, 2023 - 2029, USD Million
TABLE 61 South Korea Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
TABLE 62 South Korea Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
TABLE 63 South Korea Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 64 South Korea Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 65 South Korea Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
TABLE 66 South Korea Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
TABLE 67 Singapore Leukemia Therapeutics Market, 2019 - 2022, USD Million
TABLE 68 Singapore Leukemia Therapeutics Market, 2023 - 2029, USD Million
TABLE 69 Singapore Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
TABLE 70 Singapore Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
TABLE 71 Singapore Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 72 Singapore Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 73 Singapore Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
TABLE 74 Singapore Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
TABLE 75 Malaysia Leukemia Therapeutics Market, 2019 - 2022, USD Million
TABLE 76 Malaysia Leukemia Therapeutics Market, 2023 - 2029, USD Million
TABLE 77 Malaysia Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
TABLE 78 Malaysia Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
TABLE 79 Malaysia Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 80 Malaysia Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 81 Malaysia Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
TABLE 82 Malaysia Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
TABLE 83 Rest of Asia Pacific Leukemia Therapeutics Market, 2019 - 2022, USD Million
TABLE 84 Rest of Asia Pacific Leukemia Therapeutics Market, 2023 - 2029, USD Million
TABLE 85 Rest of Asia Pacific Leukemia Therapeutics Market by Drug Class, 2019 - 2022, USD Million
TABLE 86 Rest of Asia Pacific Leukemia Therapeutics Market by Drug Class, 2023 - 2029, USD Million
TABLE 87 Rest of Asia Pacific Leukemia Therapeutics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 88 Rest of Asia Pacific Leukemia Therapeutics Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 89 Rest of Asia Pacific Leukemia Therapeutics Market by Type, 2019 - 2022, USD Million
TABLE 90 Rest of Asia Pacific Leukemia Therapeutics Market by Type, 2023 - 2029, USD Million
TABLE 91 Key Information - Gilead Sciences, Inc.
TABLE 92 Key Information - Bristol Myers Squibb Company
TABLE 93 Key Information - Sanofi S.A.
TABLE 94 Key information - AbbVie, Inc.
TABLE 95 Key Information - Teva Pharmaceuticals Industries Ltd.
TABLE 96 Key Information - Lupin Limited
TABLE 97 Key Information - Amgen, Inc.
TABLE 98 Key Information - Takeda Pharmaceutical Company Limited
TABLE 99 Key Information - Pfizer, Inc.
TABLE 100 Key Information - Novartis AG

List of Figures

FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 4 Key Strategic Move: (Partnerships, Collaborations & Agreements: 2019, May - 2022, Dec) Leading Players
FIG 5 Asia Pacific Leukemia Therapeutics Market Share by Drug Class, 2022
FIG 6 Asia Pacific Leukemia Therapeutics Market Share by Drug Class, 2029
FIG 7 Asia Pacific Leukemia Therapeutics Market by Drug Class, 2019 - 2029, USD Million
FIG 8 Asia Pacific Leukemia Therapeutics Market Share by Distribution Channel, 2022
FIG 9 Asia Pacific Leukemia Therapeutics Market Share by Distribution Channel, 2029
FIG 10 Asia Pacific Leukemia Therapeutics Market by Distribution Channel, 2019 - 2029, USD Million
FIG 11 Asia Pacific Leukemia Therapeutics Market Share by Type, 2022
FIG 12 Asia Pacific Leukemia Therapeutics Market Share by Type, 2029
FIG 13 Asia Pacific Leukemia Therapeutics Market by Type, 2019 - 2029, USD Million
FIG 14 Asia Pacific Leukemia Therapeutics Market Share by Country, 2022
FIG 15 Asia Pacific Leukemia Therapeutics Market Share by Country, 2029
FIG 16 Asia Pacific Leukemia Therapeutics Market by Country, 2019 - 2029, USD Million
FIG 17 Recent strategies and developments: Gilead Sciences, Inc.
FIG 18 Recent strategies and developments: Bristol Myers Squibb Company
FIG 19 Recent strategies and developments: Sanofi S.A.

Asia Pacific Leukemia Therapeutics Market Size, Share & Industry Trends Analysis Report By Drug Class (Targeted Therapy & Immunotherapy and Chemotherapy), By Distribution Channel, By Type, By Country and Growth Forecast, 2023 - 2029

Description

Table of Contents